A comparative study of the CYP450 inhibition potential of marketed drugs using two fluorescence based assay platforms routinely used in the pharmaceutical industry

Mahmud Kajbaf (Lead / Corresponding author), Raffaele Longhi (Research group member), Dino Montanari (Research group member), Federica Vinco (Research group member), Monica Rigo (Research group member), Stefano Fontano (Research group member), Kevin D. Read

    Research output: Contribution to journalArticle

    14 Citations (Scopus)

    Abstract

    Semi-automated high throughput screening for the inhibition of major human cytochrome P450 enzymes (1A2, 2C9, 2C19, 2D6 and 3A4) expressed in Escherichia Coli (Cypex bactosomes) or human lymphoblastoid cells (Gentest
    cDNA microsomes) using fluorescent probes has been evaluated using 68 marketed drugs. In general lower IC50 values were obtained with Cypex bactosomes compared with Gentest cDNA microsomes. This could be due to use of higher concentration of protein and also the lower activity of Gentest cDNA microsomes. Notably, when compared with in vivo clinical drug-drug interactions (cDDIs) gathered from clinical studies reported in the scientific literature Cypex bactosome data was better at predicting in vivo cDDI. Consequently, from the data obtained in this comparative study, a fluorescence based assay using Cypex bactosomes is more suitable as a front-line screen for the prediction of potential downstream CYP450 driven cDDIs.
    Original languageEnglish
    Pages (from-to)30-39
    Number of pages10
    JournalDrug Metabolism Letters
    Volume5
    Issue number1
    DOIs
    Publication statusPublished - 2012

    Fingerprint

    Drug Industry
    Drug interactions
    Assays
    Microsomes
    Fluorescence
    Drug Interactions
    Pharmaceutical Preparations
    Cytochrome P-450 Enzyme System
    Industry
    Complementary DNA
    Literature
    Cytochrome P-450 CYP1A2
    Fluorescent Dyes
    Escherichia coli
    Inhibitory Concentration 50
    Screening
    Throughput
    Proteins

    Cite this

    Kajbaf, Mahmud ; Longhi, Raffaele ; Montanari, Dino ; Vinco, Federica ; Rigo, Monica ; Fontano, Stefano ; Read, Kevin D. / A comparative study of the CYP450 inhibition potential of marketed drugs using two fluorescence based assay platforms routinely used in the pharmaceutical industry. In: Drug Metabolism Letters. 2012 ; Vol. 5, No. 1. pp. 30-39.
    @article{b9a4e0de08114466a58b6f8ef70c2d48,
    title = "A comparative study of the CYP450 inhibition potential of marketed drugs using two fluorescence based assay platforms routinely used in the pharmaceutical industry",
    abstract = "Semi-automated high throughput screening for the inhibition of major human cytochrome P450 enzymes (1A2, 2C9, 2C19, 2D6 and 3A4) expressed in Escherichia Coli (Cypex bactosomes) or human lymphoblastoid cells (GentestcDNA microsomes) using fluorescent probes has been evaluated using 68 marketed drugs. In general lower IC50 values were obtained with Cypex bactosomes compared with Gentest cDNA microsomes. This could be due to use of higher concentration of protein and also the lower activity of Gentest cDNA microsomes. Notably, when compared with in vivo clinical drug-drug interactions (cDDIs) gathered from clinical studies reported in the scientific literature Cypex bactosome data was better at predicting in vivo cDDI. Consequently, from the data obtained in this comparative study, a fluorescence based assay using Cypex bactosomes is more suitable as a front-line screen for the prediction of potential downstream CYP450 driven cDDIs.",
    author = "Mahmud Kajbaf and Raffaele Longhi and Dino Montanari and Federica Vinco and Monica Rigo and Stefano Fontano and Read, {Kevin D.}",
    year = "2012",
    doi = "10.2174/187231211794455262",
    language = "English",
    volume = "5",
    pages = "30--39",
    journal = "Drug Metabolism Letters",
    issn = "1872-3128",
    publisher = "Bentham Science Publishers",
    number = "1",

    }

    A comparative study of the CYP450 inhibition potential of marketed drugs using two fluorescence based assay platforms routinely used in the pharmaceutical industry. / Kajbaf, Mahmud (Lead / Corresponding author); Longhi, Raffaele (Research group member); Montanari, Dino (Research group member); Vinco, Federica (Research group member); Rigo, Monica (Research group member); Fontano, Stefano (Research group member); Read, Kevin D.

    In: Drug Metabolism Letters, Vol. 5, No. 1, 2012, p. 30-39.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - A comparative study of the CYP450 inhibition potential of marketed drugs using two fluorescence based assay platforms routinely used in the pharmaceutical industry

    AU - Kajbaf, Mahmud

    AU - Read, Kevin D.

    A2 - Longhi, Raffaele

    A2 - Montanari, Dino

    A2 - Vinco, Federica

    A2 - Rigo, Monica

    A2 - Fontano, Stefano

    PY - 2012

    Y1 - 2012

    N2 - Semi-automated high throughput screening for the inhibition of major human cytochrome P450 enzymes (1A2, 2C9, 2C19, 2D6 and 3A4) expressed in Escherichia Coli (Cypex bactosomes) or human lymphoblastoid cells (GentestcDNA microsomes) using fluorescent probes has been evaluated using 68 marketed drugs. In general lower IC50 values were obtained with Cypex bactosomes compared with Gentest cDNA microsomes. This could be due to use of higher concentration of protein and also the lower activity of Gentest cDNA microsomes. Notably, when compared with in vivo clinical drug-drug interactions (cDDIs) gathered from clinical studies reported in the scientific literature Cypex bactosome data was better at predicting in vivo cDDI. Consequently, from the data obtained in this comparative study, a fluorescence based assay using Cypex bactosomes is more suitable as a front-line screen for the prediction of potential downstream CYP450 driven cDDIs.

    AB - Semi-automated high throughput screening for the inhibition of major human cytochrome P450 enzymes (1A2, 2C9, 2C19, 2D6 and 3A4) expressed in Escherichia Coli (Cypex bactosomes) or human lymphoblastoid cells (GentestcDNA microsomes) using fluorescent probes has been evaluated using 68 marketed drugs. In general lower IC50 values were obtained with Cypex bactosomes compared with Gentest cDNA microsomes. This could be due to use of higher concentration of protein and also the lower activity of Gentest cDNA microsomes. Notably, when compared with in vivo clinical drug-drug interactions (cDDIs) gathered from clinical studies reported in the scientific literature Cypex bactosome data was better at predicting in vivo cDDI. Consequently, from the data obtained in this comparative study, a fluorescence based assay using Cypex bactosomes is more suitable as a front-line screen for the prediction of potential downstream CYP450 driven cDDIs.

    U2 - 10.2174/187231211794455262

    DO - 10.2174/187231211794455262

    M3 - Article

    VL - 5

    SP - 30

    EP - 39

    JO - Drug Metabolism Letters

    JF - Drug Metabolism Letters

    SN - 1872-3128

    IS - 1

    ER -